CN103012345A - Luteolin alpha crystal form substance, preparation method thereof as well as pharmaceutical composition and application thereof - Google Patents
Luteolin alpha crystal form substance, preparation method thereof as well as pharmaceutical composition and application thereof Download PDFInfo
- Publication number
- CN103012345A CN103012345A CN2012105357764A CN201210535776A CN103012345A CN 103012345 A CN103012345 A CN 103012345A CN 2012105357764 A CN2012105357764 A CN 2012105357764A CN 201210535776 A CN201210535776 A CN 201210535776A CN 103012345 A CN103012345 A CN 103012345A
- Authority
- CN
- China
- Prior art keywords
- luteolin
- alpha
- crystal
- crystal form
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses an alpha crystal form substance of luteolin with chemical name of 5,7,3',4'-tetrahydroxy flavone) compound and a preparation method thereof, a pharmaceutical composition containing mixed crystal forms of luteolin alpha crystal forms and alpha crystal forms in any proportion and an application of the luteolin crystal form substance used as effective pharmaceutical ingredients in preparation of medicines used for preventing and treating nervous system disease, cardiocerebral vascular system disease, digestive system disease, inflammation and infectious diseases.
Description
Technical field
The invention discloses two kinds of crystal-form substances of compound of luteolin and preparation method thereof, the pharmaceutical composition that contains luteolin alpha-crystal form, beta crystal and (alpha+beta) mixing crystal formation, reach the luteolin crystal-form substances as effective ingredient, the application in nervous system disorders, diseases of cardiovascular and cerebrovascular systems, digestive system, disease of immune system, inflammation and the infectious diseases.
Background technology
Luteolin (chemical name: 5,7,3', 4'-kaempferol; English name: Luteolin)
The luteolin molecular structure
At Chinese patent CN1613445(publication number) in put down in writing " application in suppressing the intestinal peristalsis medicine of luteolin and derivative thereof " of Dalian Inst of Chemicophysics, Chinese Academy of Sciences's invention
[1]Wherein, related to the application in suppressing the intestinal peristalsis medicine of luteolin and derivative thereof.
At Chinese patent CN1785991(publication number) in put down in writing the invention of Chuanda Huaxi Pharmaceutical Industry Co., Ltd. Sichuan Prov. and Sichuan University " a kind of anti inflammatory detoxication luteolin kind new medicine and preparation method thereof "
[3]Wherein, related to a kind of anti inflammatory detoxication luteolin kind derivative and preparation method thereof.
At Chinese patent CN1947747(publication number) in put down in writing the yellow grey hair that shakes bright " pharmaceutical composition of being made by luteolin and the capsule of weeping forsythia and its production and use "
[3]Wherein, related to the preparation method of the pharmaceutical composition that luteolin, the capsule of weeping forsythia or Fructus Forsythiae extract form and its in antibiotic, antiviral, anti-inflammatory, antitumor, analgesia, relieving cough and reducing sputum, analgesic, protect the liver, the aspect effects such as hemostasis, reducing blood-fat, anti-oxidant, immunomodulatory.
Summary of the invention
One of the object of the invention: two kinds of crystal formation solid matter samples that provide luteolin alpha-crystal form and beta crystal.
Two of the object of the invention: the process of preparing that provides two kinds of crystal formation solid matter samples of luteolin alpha-crystal form and beta crystal.
Three of the object of the invention: provide the solid pharmaceutical and the composition thereof that contain luteolin alpha-crystal form sterling, beta crystal sterling or mixed the different crystal forms that forms by (alpha+beta) crystal formation by the different ratios proportioning, comprise the different pharmaceutical dosage forms such as tablet, capsule, pill, injection, sustained release preparation, controlled release preparation.
Four of the object of the invention: provide the solid crystal formation medicine that contains luteolin alpha-crystal form, beta crystal, (alpha+beta) crystal formation in performance pharmacological agent mechanism and produce the impact of specific absorption difference.
Five of the object of the invention: provide the effect of luteolin crystal-form substances in preventing and treating nervous system disorders, diseases of cardiovascular and cerebrovascular systems or other class disease, and the therapeutic action that in treatment various diseases process, improves Plasma Concentration performance in the organism owing to the crystal formation effect.
Six of the object of the invention: provide and use luteolin alpha-crystal form, beta crystal and (alpha+beta) mixing crystal formation solid matter and the common raw material as effective ingredient of flavonoid chemical substance (or other class chemical substance) combination that becomes to grade (containing different chemical composition kind, different content proportioning), compound chemical medicine and various pharmaceutical preparation thereof that exploitation is made, and be applied to prevent and treat nervous system disorders, diseases of cardiovascular and cerebrovascular systems, digestive system, disease of immune system or reach other class diseases etc.
Seven of the object of the invention: provide and use luteolin alpha-crystal form, beta crystal and (alpha+beta) mixing crystal formation solid matter and the common raw material as effective ingredient of herbal medicine (containing Chinese medicine compound prescription, Chinese medicinal materials, extract part etc.) combinations of substances (containing different sorts, different content proportioning), herbal mixture medicine and various pharmaceutical preparation thereof that exploitation is made, and be applied to prevent and treat nervous system disorders, diseases of cardiovascular and cerebrovascular systems, digestive system, disease of immune system or reach other class diseases etc.
This patent has been found two kinds of different crystal forms (alpha-crystal form and beta crystal) solid matter existence of compound of luteolin, and has invented the preparation method of two kinds of crystal form samples; The present invention finds that there is absorptivity difference in vivo in two kinds of crystal formation solid matters of luteolin, wherein the beta crystal specific absorption is greater than alpha-crystal form, the comparable alpha-crystal form of the specific absorption of beta crystal improves more than 1.5 times, on because specific absorption is different, and the Plasma Concentration that causes thus changes and causes medicine biological action difference in performance pharmacological agent.
In addition, the present invention has found that also the luteolin crystal-form substances is different from the medical active effect of above-mentioned 3 patent reports, namely by neuroprotective, monoamine oxidase restraining effect, the re-absorbed restraining effect of neurotransmitter 5-HT, performance prevents and treats nervous system disorders and senile nervous system disorders, comprises the nerve degenerative diseases such as Parkinson's disease, senile dementia; The luteolin crystal-form substances also has preferably therapeutic action in diseases of cardiovascular and cerebrovascular systems, disease of immune system, digestive system, inflammatory reaction and infectious diseases simultaneously.
Technical characterictic
1. the morphological specificity of alpha-crystal form luteolin sample:
1.1. luteolin alpha-crystal form solid matter of the present invention is characterized in that (CuK when using powder x-ray diffraction analysis
αRadiation), show as the diffraction peak position: the 2-Theta value (°) or the d value
With the diffraction peak relative intensity: crystalline state solid matter when having following characteristic peaks of peak height value (Height%) or peak area value (Area%) (table 1, Fig. 1):
The powder x-ray diffraction characteristic peaks of table 1 alpha-crystal form luteolin sample
1.2. luteolin alpha-crystal form solid matter of the present invention when using DSC collection of illustrative plates (Fig. 2) to analyze, is characterized in that having two endotherm(ic)peaks in its DSC collection of illustrative plates, transformation value be respectively about 162 ° of C and 339 ° of C about.
1.3. luteolin alpha-crystal form solid matter of the present invention, when using the KBr compressing tablet to analyze, the infrared absorption spectrum of acquisition (Fig. 3) is characterized in that its infrared absorption exists: 3419.3,3108.5,3070.8,2978.1,2902.9,2817.9,2763.1,2694.6,2629.0,1655.3,1611.4,1576.8,1502.0,1457.3,1443.2,1401.3,1366.7,1313.3,1266.1,1251.8,1191.8,1165.0,1138.3,1120.9,1097.5,1031.7,999.2,953.9,931.6,876.9,861.2,838.4,815.7,791.2,758.1,685.6,666.9,642.1,602.6,565.1,520.1,472.1,457.4,422.7cm
-1There is an absorption peak at the place, wherein 3419.3,3108.5,3070.8,2978.1,2902.9,2763.1,2694.6,2629.0,1457.3,1191.8,953.5,931.6,758.1,666.9,472.1cm
-1The peak is the principal character absorption peak of luteolin alpha-crystal form solid matter.
2. the morphological specificity of beta crystal luteolin sample:
2.1. luteolin beta crystal solid matter of the present invention is characterized in that (CuK when using powder x-ray diffraction analysis
αRadiation), show as the diffraction peak position: the 2-Theta value (°) or the d value
With the diffraction peak relative intensity: solid matter when having following characteristic peaks of peak height value (Height%) or peak area value (Area%) (table 2, Fig. 4):
The powder x-ray diffraction characteristic peaks of table 2 beta crystal luteolin sample
2.2. luteolin beta crystal solid matter of the present invention when using DSC collection of illustrative plates (Fig. 5) to analyze, is characterized in that having two endotherm(ic)peaks in its DSC collection of illustrative plates, its transformation value is respectively about 147 ° of C and about 337 ° of C.
2.3. luteolin beta crystal solid matter of the present invention, when using the KBr compressing tablet to analyze, the infrared absorption spectrum of acquisition (Fig. 6) is characterized in that its infrared absorption exists: 3416.2,3043.0,2973.3,2896.5,2814.0,2748.1,2691.9,2622.0,1655.6,1610.7,1575.6,1502.1,1442.2,1363.9,1299.6,1264.5,1189.9,1163.8,1138.4,1119.6,1095.4,1030.4,998.3,945.6,876.0,860.5,837.0,815.3,789.6,761.5,685.3,641.2,601.4,563.2,518.1,492.9,456.7,422.8cm
-1There is an absorption peak at the place, wherein 3416.2,3043.0,2973.3,2896.5,2748.1,2691.9,2622.0,1299.6,1189.9,945.6,761.5,492.9cm
-1The peak is the principal character absorption peak of luteolin beta crystal solid matter.
3. the pharmacodynamic profile of luteolin sample:
3.1 inhibition activity of monoamine oxidase.The mixing crystal formation solid matter sample that luteolin alpha-crystal form sterling of the present invention, beta crystal sterling, the combination of (alpha+beta) crystal formation arbitrary proportion obtain, it is characterized in that having inhibition brain Inner activity of monoamine oxidase, minimizing is to the metabolism of neurotransmitter, improve the partial concn of brain Inner neurotransmitter, reach the effect of performance treatment disease.
3.2 suppressing neurotransmitter 5-HT heavily absorbs.The mixing crystal formation solid matter sample that luteolin alpha-crystal form sterling of the present invention, beta crystal sterling, the combination of (alpha+beta) crystal formation arbitrary proportion obtain, it is characterized in that having and suppress brain Inner nerve synapse to the re-absorbed restraining effect of neurotransmitter 5-HT, improve the neurotransmitter concentration in nerve synapse gap, the effect of performance disease preventing and treating.
3.3 in addition, the luteolin crystal-form substances is at cardiovascular and cerebrovascular, anti-inflammatory, immunosuppression, anti-infective and strengthen the aspect such as gastrointestinal function and all can bring into play preventive and therapeutic effect.
4. the bioavailability feature of luteolin sample:
Luteolin alpha-crystal form sterling of the present invention and beta crystal sterling all can be passed through oral absorption, but bioavailability there are differences, the bioavailability of oral beta crystal sterling is higher more than 1.5 times than alpha-crystal form, and two kinds of crystal formations make up in any proportion the mixed crystal solid matter sample that obtains and also have different bioavailability difference.
5. the dosage of luteolin sample and pharmaceutical preparation feature:
Further aspect of the present invention also relates to the pharmaceutical composition of the compounds of this invention as active ingredient.Pharmaceutical preparation feature of the present invention is to contain the mixing crystal formation solid sample that luteolin alpha-crystal form sterling, beta crystal sterling, the combination of (alpha+beta) crystal formation arbitrary proportion obtain, it is characterized in that every day dosage in the 2000mg scope with interior pharmaceutical composition.Pharmaceutical composition of the present invention, contain effective dose such as claim 1(alpha-crystal form) and or claim 4(beta crystal) and claim 7(alpha+beta mixing crystal formation) described luteolin solid matter and pharmaceutically acceptable carrier.Pharmaceutical composition also contains the flavonoid chemical substance, or also contains the herbal medicine material.Described herbal medicine material comprises Chinese medicine compound prescription, Chinese medicinal materials, extract part.This pharmaceutical composition includes the different pharmaceutical dosage forms such as tablet, capsule, pill, injection, sustained release preparation, controlled release preparation.
This pharmaceutical composition can be according to method preparation well known in the art.Can be by the pharmaceutically acceptable solid of the compounds of this invention and one or more or liquid excipient and/or assistant agent being combined, making any formulation that is suitable for human or animal's use.The content of the compounds of this invention in its pharmaceutical composition is generally the 0.1-95 % by weight.
The compounds of this invention or contain its pharmaceutical composition can the unit dosage form administration, route of administration can be enteron aisle or non-enteron aisle, such as oral, intravenous injection, intramuscular injection, subcutaneous injection, nasal cavity, oral mucosa, eye, lung and respiratory tract, skin, vagina, rectum etc.
Form of administration can be liquid dosage form, solid dosage or semisolid dosage form.Liquid dosage form can be solution (comprising true solution and colloidal solution), emulsion (comprising o/w type, w/o type and emulsion), suspensoid, injection (comprising aqueous injection, powder injection and transfusion), eye drops, nasal drop, lotion and liniment etc.; Solid dosage can be tablet (comprising ordinary tablet, enteric coated tablet, lozenge, dispersible tablet, chewable tablet, effervescent tablet, orally disintegrating tablet), capsule (comprising hard capsule, soft capsule, enteric coated capsule), granule, powder, micropill, dripping pill, suppository, film, paster, the agent of gas (powder) mist, sprays etc.; Semisolid dosage form can be ointment, gelifying agent, paste etc.
The compounds of this invention can be made ordinary preparation, also make is sustained release preparation, controlled release preparation, targeting preparation and various particulate delivery system.
For the compounds of this invention is made tablet, can be widely used various vehicle well known in the art, comprise thinner, tamanori, wetting agent, disintegrating agent, lubricant, glidant.Thinner can be starch, dextrin, sucrose, glucose, lactose, N.F,USP MANNITOL, sorbyl alcohol, Xylitol, Microcrystalline Cellulose, calcium sulfate, secondary calcium phosphate, calcium carbonate etc.; Wetting agent can be water, ethanol, Virahol etc.; Tackiness agent can be starch slurry, dextrin, syrup, honey, glucose solution, Microcrystalline Cellulose, mucialga of arabic gummy, gelatine size, Xylo-Mucine, methylcellulose gum, Vltra tears, ethyl cellulose, acrylic resin, carbomer, polyvinylpyrrolidone, polyoxyethylene glycol etc.; Disintegrating agent can be dry starch, Microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, cross-linked polyvinylpyrrolidone, croscarmellose sodium, sodium starch glycolate, sodium bicarbonate and Citric Acid, polyoxyethylene sorbitol fatty acid ester, sodium laurylsulfonate etc.; Lubricant and glidant can be talcum powder, silicon-dioxide, stearate, tartrate, whiteruss, polyoxyethylene glycol etc.
Tablet further can also be made coating tablet, for example sugar coated tablet, thin membrane coated tablet, ECT, or double-layer tablets and multilayer tablet.
For capsule is made in the administration unit, the effective constituent the compounds of this invention can be mixed with thinner, glidant, mixture is directly placed hard capsule or soft capsule.Also can with effective constituent the compounds of this invention elder generation and thinner, tamanori, disintegrating agent granulation or micropill, place again hard capsule or soft capsule.The capsule that also can be used for preparing the compounds of this invention for the preparation of each thinner, tamanori, wetting agent, disintegrating agent, the glidant kind of the compounds of this invention tablet.
For the compounds of this invention is made injection, can water, ethanol, Virahol, propylene glycol or their mixture as solvent and add an amount of this area solubilizing agent commonly used, solubility promoter, pH and adjust agent, osmotic pressure regulator.Solubilizing agent or solubility promoter can be poloxamer, Yelkin TTS, hydroxypropyl-beta-cyclodextrin etc.; PH adjustment agent can be phosphoric acid salt, acetate, hydrochloric acid, sodium hydroxide etc.; Osmotic pressure regulator can be sodium-chlor, N.F,USP MANNITOL, glucose, phosphoric acid salt, acetate etc.As prepare lyophilized injectable powder, also can add N.F,USP MANNITOL, glucose etc. as propping agent.
In addition, such as needs, also can in pharmaceutical preparation, add tinting material, sanitas, spices, correctives or other additive.
For reaching the medication purpose, strengthen result for the treatment of, medicine of the present invention or pharmaceutical composition can be with any known medication administrations.
The dosage of the compounds of this invention pharmaceutical composition is according to character and the severity that will prevent or treat disease, the individual instances of patient or animal, and route of administration and formulation etc. can have large-scale variation.In general, the suitable dose scope of the every day of the compounds of this invention is the 0.001-150mg/Kg body weight, is preferably the 0.1-100mg/Kg body weight, and more preferably the 1-60mg/Kg body weight most preferably is the 2-30mg/Kg body weight.Above-mentioned dosage can a dose unit or is divided into several dose unit administrations, and this depends on doctor's clinical experience and comprises the dosage regimen of using other treatment means.
Compound of the present invention or composition can be taken separately, or merge use with other treatment medicine or symptomatic drugs.When compound of the present invention and other medicine existence synergy, should adjust according to practical situation its dosage.
Description of drawings
The x-ray diffractogram of powder spectrum of Fig. 1 alpha-crystal form luteolin sample
The DSC collection of illustrative plates of Fig. 2 alpha-crystal form luteolin sample
The infrared absorption pattern of Fig. 3 alpha-crystal form luteolin sample
The x-ray diffractogram of powder spectrum of Fig. 4 beta crystal luteolin sample
The DSC collection of illustrative plates of Fig. 5 beta crystal luteolin sample
The infrared absorption pattern of Fig. 6 beta crystal luteolin sample
Different time blood Chinese traditional medicine concentration behind Fig. 7 luteolin Oral Administration in Rats (300mg/kg)
Fig. 8 luteolin (5 μ g/ml) is to monoamine oxidase and the re-absorbed restraining effect of 5-HT
Embodiment
Be better explanation technical scheme of the present invention, the spy provides following examples, but the present invention is not limited to this content.
The crystal formation preparation
The preparation method 1 of luteolin alpha-crystal form sample:
A kind of preparation method of luteolin alpha-crystal form sample is characterized in that using the single solvent systems such as chloroform, acetone, ethyl acetate, propyl carbinol, acetonitrile, tetrahydrofuran (THF), dioxane, Glacial acetic acid, formic acid, ether, methylene dichloride, toluene, benzene, normal hexane, hexanaphthene, dioxane, DMF, sherwood oil, ammoniacal liquor, n-propyl alcohol, water.First the luteolin sample is dissolved fully, is placed on temperature range at 4 ° of C to 350 ° of C, the relative humidity scope 90% with interior environment under, through recrystallization growth time 1 day to 60 days, the alpha-crystal form solid sample that finally prepares.
The preparation method 2 of luteolin alpha-crystal form sample:
A kind of preparation method of luteolin alpha-crystal form sample, it is characterized in that using methyl alcohol, ethanol, Virahol, 95% ethanol, chloroform, acetone, ethyl acetate, propyl carbinol, acetonitrile, tetrahydrofuran (THF), dioxane, Glacial acetic acid, formic acid, ether, methylene dichloride, toluene, benzene, normal hexane, hexanaphthene, dioxane, DMF, sherwood oil, ammoniacal liquor, n-propyl alcohol, water equal solvent kind, the mixed solvent system of making through various combination (two or more solvent use) and different proportionings.First the luteolin sample is dissolved fully, is placed on temperature range at 4 ° of C to 350 ° of C, the relative humidity scope 90% with interior environment under, through recrystallization growth time 1 day to 60 days, the alpha-crystal form solid sample that finally prepares.
The preparation method 1 of luteolin beta crystal sample:
The preparation method of luteolin beta crystal sample is characterized in that using luteolin alpha-crystal form solid sample as raw material, turns the beta crystal solid sample that brilliant technique and other physics rotating crystal method prepare through solid abrasive, heating etc.
Embodiment 4
The preparation method 2 of luteolin beta crystal sample:
The preparation method of luteolin beta crystal sample, after it is characterized in that using the single solvent systems such as chloroform, acetone, ethyl acetate, propyl carbinol, acetonitrile, tetrahydrofuran (THF), dioxane, Glacial acetic acid, formic acid, ether, methylene dichloride, toluene, benzene, normal hexane, hexanaphthene, dioxane, DMF, sherwood oil, ammoniacal liquor, n-propyl alcohol, water with the luteolin sample dissolution, re-use the cold spray method and obtain fast the beta crystal solid sample.
Preparation
The preparation method 1(tablet of combined pharmaceutical formulation):
A kind of preparation method of combined pharmaceutical formulation, it is characterized in that using solid matter that several vehicle mix by the different ratios proportioning with luteolin alpha-crystal form sterling, beta crystal sterling or by (alpha+beta) crystal formation as the bulk drug of medicinal composition, make every content of dispersion at the tablet of 10 ~ 500mg, table 3 provides tablet formulation:
The preparation prescription of table 3 luteolin medicinal composition tablet
With luteolin alpha-crystal form sterling, beta crystal sterling or by the method that the bulk drug that (alpha+beta) crystal formation mixes by the different ratios proportioning is prepared into tablet formulation be: several vehicle and bulk drug are mixed, add 1% sodium cellulose glycolate solution an amount of, make soft material, the granulation of sieving, wet grain oven dry, the whole grain that sieves adds Magnesium Stearate and talcum powder and mixes, compressing tablet, and get final product.
Embodiment 6
The preparation method 2(capsule of combined pharmaceutical formulation):
A kind of preparation method of combined pharmaceutical formulation, it is characterized in that using solid matter that several vehicle mix by the different ratios proportioning with luteolin alpha-crystal form sterling, beta crystal sterling or by (alpha+beta) crystal formation as the bulk drug of medicinal composition, make every content of dispersion at the capsule of 10 ~ 500mg, table 4 provides capsule formula:
The preparation prescription of table 4 luteolin medicinal composition capsule
With luteolin alpha-crystal form sterling, beta crystal sterling or by the method that the bulk drug that (alpha+beta) crystal formation mixes by the different ratios proportioning is prepared into capsule preparations be: several vehicle and bulk drug are mixed, add 1% sodium cellulose glycolate solution an amount of, make wet grain, oven dry, whole grain sieves, add Magnesium Stearate, mix, insert capsule and make.Or do not use granulation step, and and directly that bulk drug and several mixed with excipients is even, after sieving, directly incapsulate and make.
Pharmacological evaluation
The luteolin solid material medicine of alpha-crystal form and beta crystal Absorption Characteristics and Plasma Concentration feature in vivo:
Give pure alpha-crystal form, pure beta crystal, (alpha+beta) mixing crystal formation luteolin solid material medicinal powder end to cleaning level rat stomach Inner, dosage is 300mg/kg, after administration, extract in the different time points rat artery hematometry content of luteolin (table 5, Fig. 7).The result proves: the luteolin bulk drug of different crystal forms under the condition of oral same dosage, the drug level in the blood and the asynchronism(-nization) of concentration of peaking, wherein the Plasma Concentration of alpha-crystal form is starkly lower than the Plasma Concentration of beta crystal.
The Plasma Concentration (HPLC detection) of different time behind the table 5 Oral Administration in Rats luteolin different crystal forms sample
Embodiment 8
Luteolin (5 μ g/ml) is to monoamine oxidase and the re-absorbed restraining effect of 5-HT:
Respectively monoamine oxidase is had obvious restraining effect by Bioexperiment proof luteolin (5 μ g/ml), 5-HT is heavily absorbed also has obvious restraining effect (Fig. 8) simultaneously.Illustrate that luteolin has therapeutic action to nervous system disorders and diseases of cardiovascular and cerebrovascular systems, particularly nerve degenerative diseases and senile nervous system disease have preventive and therapeutic effect.
Embodiment 9
Adopt 6-OHDA (6-OHDA) damage SD rat brain dopaminergic neuron, preparation Parkinson's disease (PD) model, induce the PD symptom with apomorphine (APO) abdominal injection (0.5mg/kg), visible animal is all of a tremble, the back of a bow, perpendicular tail, tremble, movable slow, grasp, smell the symptom of visiting and rotatablely move etc.By the number of turns that rotatablely moves of record animal, estimate animal movement behavior disorder degree, the result proves, animal model is successfully prepared.Luteolin to the circling behavior of animal pattern without obvious effect, and with positive drug madopar there was no significant difference relatively, the results are shown in Table 6.
Table 6 luteolin is on the circling behavior impact of 6-OHDA damage SD rat
Adopt 6-OHDA (6-OHDA) damage SD rat brain dopaminergic neuron, preparation Parkinson's disease (PD) model, induce the PD symptom with apomorphine (APO) abdominal injection (0.5mg/kg), visible animal is all of a tremble, the back of a bow, perpendicular tail, tremble, movable slow, grasp, smell the symptom such as spy.By the myoelectrical activity of record animal hindlimb muscle, estimate degree and the drug effect of PD symptom.The result as seen, luteolin can significantly reduce animal pattern muscular tremor frequency and amplitude (with model group relatively, P＜0.05), effect is better than the positive drug madopar, the results are shown in Table 7.
Table 7 luteolin is on the impact of trembling of 6-OHDA damage SD rat
Annotate: compare * P＜0.05, * * P＜0.01 with model group.
Claims (8)
1. the alpha-crystal form of luteolin is characterized in that, when using powder x-ray diffraction analysis to adopt CuK
αDuring the radiation experiments condition, the diffraction peak position: the 2-Theta value (°) or the d value
With the diffraction peak relative intensity: peak height value (Height%) or peak area value (Area%) have following feature:
2. a luteolin mixed crystal contains luteolin alpha-crystal form as claimed in claim 1 and luteolin beta crystal that arbitrary proportion mixes; Wherein said luteolin beta crystal is when using powder x-ray diffraction analysis to adopt CuK
αDuring the radiation experiments condition, the diffraction peak position: the 2-Theta value (°) or the d value
With the diffraction peak relative intensity: peak height value (Height%) or peak area value (Area%) have following feature:
3. the preparation method of a luteolin alpha-crystal form as claimed in claim 1, it is characterized in that, use chloroform, acetone, ethyl acetate, propyl carbinol, acetonitrile, tetrahydrofuran (THF), dioxane, Glacial acetic acid, formic acid, ether, methylene dichloride, toluene, benzene, normal hexane, hexanaphthene, DMF, sherwood oil, ammoniacal liquor, n-propyl alcohol, water single solvent system; First the luteolin sample is dissolved fully, is placed on temperature range at 4 ° of C to 350 ° of C, the relative humidity scope 90% with interior environment under, through recrystallization growth time 1 day to 60 days, the alpha-crystal form solid sample that finally prepares.
4. the preparation method of a luteolin alpha-crystal form as claimed in claim 1, it is characterized in that, use methyl alcohol, ethanol, Virahol, chloroform, acetone, ethyl acetate, propyl carbinol, acetonitrile, tetrahydrofuran (THF), dioxane, Glacial acetic acid, formic acid, ether, methylene dichloride, toluene, benzene, normal hexane, hexanaphthene, DMF, sherwood oil, ammoniacal liquor, n-propyl alcohol, water solvent kind, the mixed solvent system of making by different proportionings through two or more solvent; First the luteolin sample is dissolved fully, is placed on temperature range at 4 ° of C to 350 ° of C, the relative humidity scope 90% with interior environment under, through recrystallization growth time 1 day to 60 days, the alpha-crystal form solid sample that finally prepares.
5. a pharmaceutical composition contains the luteolin alpha-crystal form as claimed in claim 1 of effective dose and luteolin mixed crystal and the pharmaceutically acceptable carrier of or claim 2.
6. according to claim 5 pharmaceutical composition is characterized in that, described pharmaceutical composition is tablet, capsule, pill, injection, sustained release preparation, controlled release preparation.
Luteolin alpha-crystal form claimed in claim 1 and luteolin mixed crystal claimed in claim 2 the preparation prevention and or the medicine for the treatment of nervous system disorders, diseases of cardiovascular and cerebrovascular systems, digestive system, disease of immune system, inflammation and infectious diseases in application.
8. according to claim 7 application is characterized in that described nervous system disorders comprises nerve degenerative diseases, depression, the anxieties such as Parkinson's disease, senile dementia; Described diseases of cardiovascular and cerebrovascular systems comprises hypertension, cerebral thrombosis, hyperlipidemia, Intracerebral hemorrhage, coronary heart disease; Described digestive system comprises gastritis, intestinal peristalsis; Described disease of immune system comprises diabetes, asthma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210535776.4A CN103012345B (en) | 2007-11-09 | 2007-11-09 | Luteolin alpha crystal form substance, preparation method thereof as well as pharmaceutical composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210535776.4A CN103012345B (en) | 2007-11-09 | 2007-11-09 | Luteolin alpha crystal form substance, preparation method thereof as well as pharmaceutical composition and application thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200710177084 Division CN101429184B (en) | 2007-11-09 | 2007-11-09 | Two-crystal type of substance of luteolin, production method, medicament composition and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103012345A true CN103012345A (en) | 2013-04-03 |
| CN103012345B CN103012345B (en) | 2014-11-26 |
Family
ID=47961502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210535776.4A Active CN103012345B (en) | 2007-11-09 | 2007-11-09 | Luteolin alpha crystal form substance, preparation method thereof as well as pharmaceutical composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103012345B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107550924A (en) * | 2017-09-15 | 2018-01-09 | 刘锐 | The glucosulfone aldehydic acid glycosides of cyanidenon 7 and its application with the composition of doxepin in the medicine for preparing treatment depression |
| CN109198628A (en) * | 2018-10-10 | 2019-01-15 | 陶燃 | A kind of composition and application thereof for treating depression and anxiety disorder |
| CN110507645A (en) * | 2019-09-24 | 2019-11-29 | 广东工业大学 | The application of luteolin |
| CN110693870A (en) * | 2018-07-10 | 2020-01-17 | 南方医科大学 | Application of luteolin in preparation of medicine for relieving insulin beta intracellular reticulum stress |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000026206A1 (en) * | 1998-10-30 | 2000-05-11 | Merck Patent Gmbh | Method for producing luteolin and luteolin derivatives |
| CN1544427A (en) * | 2003-11-20 | 2004-11-10 | 黑龙江大学 | Luteolin semi-synthesis method |
-
2007
- 2007-11-09 CN CN201210535776.4A patent/CN103012345B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000026206A1 (en) * | 1998-10-30 | 2000-05-11 | Merck Patent Gmbh | Method for producing luteolin and luteolin derivatives |
| CN1544427A (en) * | 2003-11-20 | 2004-11-10 | 黑龙江大学 | Luteolin semi-synthesis method |
Non-Patent Citations (4)
| Title |
|---|
| DHANAPALAN NAGARATHNAM AND MARK CUSHMAN: "A Short and Facile Synthetic Route to Hydroxylated Flavones. New Syntheses of Apigenin,Tricin, and Luteolin", 《J. ORG. CHEM.》 * |
| 张印俊等: "多舌飞蓬黄酮成分的研究", 《中草药》 * |
| 戈夏等: "木犀草素和奥洛波尔的合成", 《中国医药工业杂志》 * |
| 郑宗忠等: "腐婢根化学成分研究", 《亚热带植物科学》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107550924A (en) * | 2017-09-15 | 2018-01-09 | 刘锐 | The glucosulfone aldehydic acid glycosides of cyanidenon 7 and its application with the composition of doxepin in the medicine for preparing treatment depression |
| CN110693870A (en) * | 2018-07-10 | 2020-01-17 | 南方医科大学 | Application of luteolin in preparation of medicine for relieving insulin beta intracellular reticulum stress |
| CN109198628A (en) * | 2018-10-10 | 2019-01-15 | 陶燃 | A kind of composition and application thereof for treating depression and anxiety disorder |
| CN110507645A (en) * | 2019-09-24 | 2019-11-29 | 广东工业大学 | The application of luteolin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103012345B (en) | 2014-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101434593B (en) | Two crystal substances of baicalin, and preparations, pharmaceutical composition and uses thereof | |
| WO2013060258A1 (en) | Clavatine a-c, preparation method thereof and pharmaceutical composition and use thereof | |
| CN101747305B (en) | Five crystal forms of nicousamide compound and preparation method, pharmaceutical composition and usage thereof | |
| CN101429184B (en) | Two-crystal type of substance of luteolin, production method, medicament composition and uses thereof | |
| CN103012345B (en) | Luteolin alpha crystal form substance, preparation method thereof as well as pharmaceutical composition and application thereof | |
| CN101429185B (en) | Two-crystal type of substance of meletin, production method, medicament composition and uses thereof | |
| CN108699020B (en) | Novel dapagliflozin crystal form and preparation method and application thereof | |
| CN104844591A (en) | Tropisetron hydrochloride crystal form II substance, preparation method, composition and uses thereof | |
| CN101843627B (en) | Application of dihydrophenanthrene glycoside compound in preparing medicines for preventing and curing cardiovascular and cerebrovascular diseases | |
| CN101899041B (en) | Superior medicinal crystal-form solid substance of puerarin as well as preparation method and application thereof | |
| CN101898962B (en) | Rhein crystal B-type solid matter, preparation method and use | |
| CN103058976B (en) | Quercetin alpha crystal-form substance, preparation method thereof, pharmaceutical composition thereof and purpose thereof | |
| CN101857622B (en) | Adenosine derivative, and preparation method and application thereof | |
| CN113214207B (en) | Hesperetin and betaine eutectic A, preparation method, composition and application thereof | |
| CN101899053B (en) | C crystal form solid matter of bergenin and preparation method and application thereof | |
| CN113214208A (en) | Hesperetin and isonicotinamide eutectic crystal, preparation method, composition and application thereof | |
| CN113214209A (en) | Hesperetin and carbamazepine eutectic compound, preparation method, composition and application thereof | |
| CN113214206A (en) | Hesperetin and betaine eutectic compound B, preparation method, composition and application thereof | |
| CN108239126B (en) | Salicylic acid methyl ester lactoside crystal III type solid matter, preparation method, composition and application thereof | |
| CN103788044B (en) | Nicousamide crystalline substance I type, its preparation method and its pharmaceutical composition and purposes | |
| CN118290384A (en) | Daidzein and piperazine eutectic compound, preparation method, composition and application thereof | |
| CN101906100A (en) | Rotundine crystalline C-type solid substance and preparation method as well as application | |
| JP2020533369A (en) | Method for preparing thymoquinone-containing composition | |
| CN109988216A (en) | Betulin crystalline substance D type substance and preparation method and its composition and purposes | |
| CN108239079A (en) | Mangiferin V type substance of crystalline substance and preparation method and its composition and purposes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |